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Background: Over-the-counter (OTC) feminine hygiene products come with little warning about possible side
effects. This study evaluates in-vitro their effects on Lactobacillus crispatus, which is dominant in the normal
vaginal microbiota and helps maintain a healthy mucosal barrier essential for normal reproductive function
and prevention of sexually transmitted infections and gynecologic cancer.
Methods: A feminine moisturizer (Vagisil), personal lubricant, and douche were purchased OTC. A topical
spermicide (nonoxynol-9) known to alter the vaginal immune barrier was used as a control. L. crispatus was
incubated with each product for 2 and 24h and then seeded on agar for colony forming units (CFU). Human
vaginal epithelial cells were exposed to products in the presence or absence of L. crispatus for 24h, followed
by epithelium-associated CFU enumeration. Interleukin-8 was immunoassayed and ANOVA was used for
statistical evaluation.
Results: Nonoxynol-9 and Vagisil suppressed Lactobacillus growth at 2h and killed all bacteria at 24h. The
lubricant decreased bacterial growth insignificantly at 2h but killed all at 24h. The douche did not have a
significant effect. At full strength, all products suppressed epithelial viability and all, except the douche,
suppressed epithelial-associated CFU. When applied at non-toxic dose in the absence of bacteria, the douche
and moisturizer induced an increase of IL-8, suggesting a potential to initiate inflammatory reaction. In the
presence of L. crispatus, the proinflammatory effects of the douche and moisturizer were countered, and IL-8
production was inhibited in the presence of the other products.
Conclusion: Some OTC vaginal products may be harmful to L. crispatus and alter the vaginal immune
environment. Illustrated through these results, L. crispatus is essential in the preservation of the function of
vaginal epithelial cells in the presence of some feminine hygiene products. More research should be invested
toward these products before they are placed on the market.
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Introduction
Numerous women use feminine hygiene products every
day; for some, it is part of their daily cleansing. Feminine
hygiene products or methods may upset the normal pH
level of 4.5 in the vagina, which is important for
maintaining the healthy vaginal immune barrier environ-
ment (1). Through the change of pH or through direct
bactericidal properties, such products and practices may
affect the composition of the normal vaginal microbiome,
which is essential for the healthy mucosal environment
and protection against yeast infection or other sexually
transmitted pathogens. Vaginal lactobacilli are also im-
portant for having a healthy pregnancy and may pre-
vent premature delivery and illness in the newborns (2).
The disturbance of the normal microbiome, a condition
called bacterial vaginosis (BV), is associated with sig-
nificant risks for women’s health as well as inflam-
matory complications in the newborn (3), while the
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presence of Lactobacillus has been associated with lower
risk of inflammation (2). Lactobacilli and, especially,
L. crispatus are among the bacteria that are most
common in healthy women and characteristic for the
healthy vaginal environment (4, 5). Lactobacilli are
anaerobic bacteria that convert lactose and other sugars
into lactic acid, which has a role in preventing infections
(4). Lactobacillus is found in the gut and vagina, where
it has anti-inflammatory and anti-cancer activities. In
the industry, it is used to make yogurt and cheese,
and it can also be used as a biotherapeutic. Because of
its beneficial properties to the host, some Lactobacillus
species have been used as probiotics available over the
counter to aid mucosal health, for example, in the
digestive tract. Lactobacillus products are also under
investigation to restore vaginal health after prolonged use
of antibiotics or to cure BV and prevent urinary tract
infections (6, 7). L. crispatus has been found to effectively
help inhibit the growth of harmful pathogenic micro-
organisms such as Neisseria gonorrhoeae (8). This study
applied an experimental system for safety evaluation of
vaginal products by testing their effects on L. crispatus
growth and survival in-vitro. The evaluation was carried
out by comparing products representing over-the-counter
(OTC) douche kits, moisturizers, and lubricants to cell
culture medium that maintains the growth of Lactobacilli
in-vitro and nonoxynol-9 (N-9), a spermicide known to
upset the vaginal immune barrier (911).
Materials and methods
Test products
The test articles listed in Table 1 (Vagisil Feminine
Moisturizer, personal lubricant and moisturizer, and
CareOne Douche) were purchased over the counter and
were stored completely sealed, in their original box, at
room temperature. The selection of products was made
based on availability and public knowledge on each of
the products. Once purchased, each product was screened
to check for sterility. This was done by seeding each
product undiluted over agar plates. None of the products
showed any bacterial growth in this test. Phosphate-
buffered saline (PBS) (Invitrogen by Life Technologies,
Carlsbad, CA) and keratinocyte serum-free medium
(KSFM) (Invitrogen, Carlsbad, CA) supplemented
with epidermal growth factor, bovine pituitary extract,
and CaCl2 as described (12) were obtained from Invitro-
gen, Carlsbad, CA. Nonoxynol-9 (N-9) was obtained
from Personal Products Company (Skillman, NJ) (13)
and diluted to 2% with KSFM. For assessing their effect
on bacterial growth, all products were applied at 1:1 ratio
over the bacterial suspensions.
Preparation of bacterial suspension and treatment
L. crispatus was originally isolated from vaginal swab
samples from healthy women participating in a vaginal
microflora research study and then characterized and
expanded in the laboratory of Dr. A. Onderdonk,
Brigham and Women’s Hospital (14). Once the volume
needed was calculated, the frozen bacterial stocks were
thawed in a room temperature water bath. The desired
volume was transferred into a 50 mL tube and centri-
fuged down at 5000gfor 10 min at 258C. After
discarding the supernant, the bacterial pellet was resus-
pended in KSFM cell culture medium to the concen-
tration of 7106 CFU/mL. Hundred microliter of
the bacterial suspension was then added over 100
microliter undiluted product in 96-well tissue culture
plates (Becton Dickson and Company, Franklin Lakes,
NJ). The designated plates were then incubated on an
orbital shaker in an anaerobic chamber (AnaeroPack
System, PML Microbiologicals, Wilsonville, OR) at 358C
for 24 h or 2 h. From the 200 ml of test products along
with bacterial suspension, three replicates within the
same tissue culture plate were made. Each replicate con-
tained 50 ml of the mixture of product and bacteria, along
with 50ml of 50% glycerol, and was cryopreserved at
808C.
Dilution of test plates
To assess colony forming units, the bacterial suspensions
in KSFM or in test product collected at each time point
were serially diluted using 1PBS. The first row of the 96-
well plate contained L. crispatus along with the product.
The following rows contained the desired amount of
dilution in PBS achieved by transferring desired volume
from one row to another using multichannel pipettes, and
when the product had high viscosity, we used positive
displacement pipettes (Gilson Medical Electronics
through Fisher Scientific, Pittsburgh, PA).
Table 1. pH level along with ingredients listed on OTC product package
Products Ingredients (from label) Approximate pH
Vagisil Feminine
Moisturizer
Water, glycerin, propylene glycol, hydroxyethylcellulose, DMDM hydantoin, diazolidinyl urea,
disodium EDTA, polysorbate 20, methylparaben, propylparaben, Anthemis noilis (chamomille)
flower extract, polyquatternium-5, citric acid, Aloe barbadensi, tocopheryl acetate
4
CareOne Douche Purified water, benzoic acid, and vinegar 3
Personal lubricant Propylene glycol, glycerin, Trifolium pratense flower extract (clover), methylparaben 5
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Seeding bacteria over agar plates
Brucella Agar Plates with 5% sheep blood, hemin,
and vitamin K1 (BD, Franklin Lakes, NJ) were brought
out from refrigerator to adjust to room temperature for
10 minutes. A pipette tip was used to mark either halves
or thirds or the agar surface. After the serial dilutions
of L. crispatus plus product were made, 30 ml was taken
from a single well and was spread out over the agar,
using a Steriloop (Fisher Scientific, Pittsburgh, PA). The
plates were then incubated in an anaerobic chamber for
4872 h, or until there were visible colonies.
Colony forming units counts
Bacterial colonies were counted in the agar plates.
The data was then entered into Excel, multiplied by the
dilution factor, and transformed logarithmically (log10).
The average log10 data from all dilutions that generated
countable colony-forming units (CFU) for each culture in
each experiment were used for statistical analysis of the
triplicate cultures conducted in at least two independent
seeding experiments for each time point and product.
Preparation of vaginal epithelial cells and seeding
over 96-well plates
We utilized for this study an immortalized vaginal
keratinocyte cell line (Vk2/E6E7), which maintains the
differentiation patterns and phenotypic characteristics of
its normal human tissue of origin (12, 15, 16). Vaginal
cells were grown in a T75 flask using KSFM medium.
Once grown to confluence, the cells were trypsinized.
After decanting the old medium, 5 mL of warm trypsin
was added and the flask was tipped back and forth
to wash away any dead cells. After removing the trypsin,
10 mL of fresh trypsin was added and incubated for
10 min at 378C. After seven minutes, detachment of cells
was checked under a microscope. Once enough cells
were detached, equal volume of neutralization medium
was added on top of the trypsin. The cell suspensions
were then spun down at 500 g for 10 min. Next, the
supernatant was decanted, and the cells were resuspended
in 2 mL of antibiotic-free medium (AB-) and counted.
The cell density was adjusted to 3105/mL and the
suspension transferred to a sterile reservoir. Hundred
microliter of suspension was transferred per a well into
a 96-well plate. The plate was then incubated for at least
24 h before adding test products or bacterial coculture.
Epithelial cell viability and IL-8 measurement
Following 24h incubation with undiluted and diluted
test products, epithelial cell viability was assessed by
MTT assay as described (17). IL-8 levels were measured
in cell culture supernatants using a Meso Scale Discovery
(MSD) small-spot immunoassay and Sector Imager 2400
(Meso Scale Discovery, Gaithersburg, MD).
Bacterial-epithelial co-culture and epithelial-
associated CFU counts
Details on the bacterial colonization model used in this
study are published elsewhere (17). In brief, once the
vaginal keratinocytes reached 100% confluence, medium
was removed and replaced by 50 mL of bacterial
suspension and 50 mL of test product. The plate was
then placed in an anaerobic jar with one AnaeroPack
inside and incubated for 24 h. After 24 h incubation,
supernants were collected and frozen for cytokine assays.
Using 200 mL of (1) PBS, cell layers were washed in
original plate twice with a multichannel pipette. Cells
were then lysed by adding 100 ml of Hypure water and
incubated at room temperature for 15 minutes followed
by adding 100ml of (2) PBS over the Hypure water
and mixing well. Lysates were serially diluted in PBS and
seeded over agar plates with a sterile loop. Agar plates
were incubated under anaerobic conditions for 4872 h,
followed by CFU counting.
Statistical analysis
Two-tail ANOVA analysis of variance and Prism
(GraphPad Software Inc, San Diego, CA) were used
to compare the CFU values, viability, and IL-8 levels
obtained for test product and the control medium.
Results
Effect of products on planktonic L. crispatus culture
To simulate a naturally thriving environment of the
natural microbiota of the vagina, L. crispatus was
incubated at 2 and 24 h with KSFM medium, which
supports the growth of human vaginal epithelial cells
(12). Acting as a control, it was expected that under
these conditions the bacteria would grow to a suffi-
cient number of colonies. These plates were used as a
maximum threshold to compare the serial dilutions done
in the absence or presence of OTC vaginal products.
The results from the series of incubations and dilutions
concurred with the expectations for good support of
bacterial growth demonstrating recovery of CFU input
counts (Fig. 1 columns one). Acting as a bactericidal
control, N-9 was incubated along with L. crispatus for
both 2 and 24 h. As expected, N-9 had a negative effect
on the bacteria. At 24 h N-9 completely killed the
bacteria, while at 2 h, N-9 significantly (pB0.01)
decreased the number of bacterial colonies (Fig. 1). The
personal lubricant explored during this study decreased
number of bacterial colonies by less than 1 log at 2 h
incubation period (pB0.05) (Fig. 1A); however, at 24 h,
it completely prevented bacterial growth and no colo-
nies were visible from seeding of either diluted or
undiluted bacterial suspensions (Fig. 1B). Vagisil signifi-
cantly suppressed Lactobacillus growth even at a short
2 h incubation time (Fig. 1A) and at 24 h completely
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abolished bacterial colonies (Fig. 1B). The vaginal
douche tested in this study did not show any significant
effect on L. crispatus as compared to the KSFM control
(Fig. 1A and B).
Effect of products on bacterial-epithelial interactions
All products tested were toxic to the vaginal keratinocytes
when applied undiluted (at 100% dose) (Fig. 2A). The
douche was the least toxic and the moisturizer most toxic
over a set of dilutions (Fig. 2A). While the undiluted
douche stimulated bacterial growth (increasing recovery
of epithelial cell-associated CFU to 200%), the other
products suppressed bacterial growth, with the moistur-
izer being suppressive up to a 4-fold dilution (at 25%
dose) (Fig. 2B). The products had differential effects on
the production of IL-8, which is an important proin-
flammatory innate immunity mediator produced by the
vaginal epithelium to attract leukocytes to the mucosal
surface in response to infection (18, 19). In the absence of
bacteria the douche triggered increased IL-8 production
(Fig. 2C). L. crispatus counteracted this effect. In the
presence of L. crispatus, all products suppressed IL-8
production (Fig. 2D).
Discussion
The mucosal lining of the vagina provides essential
help in maintaining a healthy vaginal environment. The
results from this experimental study demonstrate that
some vaginal products may be harmful to the Lactoba-
cillus bacteria and therefore should be used with caution.
Referring to Fig. 1, both the lubricant and N-9 showed
to have a significant effect on the growth of L. crispatus.
At 24 h (Fig. 1), both the lubricant and N-9 completely
inhibited bacteria growth in our experimental system.
The results from this experimental study confirm the
hypothesis that some feminine hygiene products may
alter the vaginal immune barrier by having a negative
effect on the epithelial cell integrity (measured by MTT),
survival of beneficial Lactobacillus species in the vaginal
microenvironment (measured by epithelial-cell-associated
CFU), and by changing the ability of the vaginal epithe-
lial cells to produce protective or inflammatory immune
mediators, for example, IL-8. The results confirm clinical
findings of the harmful effects of certain vaginal hygiene
practices on susceptibility to infections. The moisturizer
and the lubricant were especially cytotoxic and negatively
affecting L. crispatus survival. The douche, on the other
hand, could promote a proinflammatory environment
in the absence of Lactobacillus or when the microbiome is
disturbed. More clinical studies are needed to test the
findings and conclusions from these experiments, which if
confirmed would argue for the benefit of using probiotics
for vaginal health.
Our results provide experimental warning that women
who have used nonoxynol-9, Vagisil, or lubricant may
have a weakened vaginal barrier due to destroyed
L. crispatus and perhaps other normal microflora species
not assessed in our study, thus becoming at risk for
the development of the syndrome of disturbed vaginal
microbiome (20). Women using such products on a regu-
lar basis should take measures such as regular use of
condoms to prevent sexually transmitted infections and
should be evaluated for BV, which can sometime be
asymptomatic and thus remain unnoticed by the vaginal
product user. Although the particular douche kit tested
did not show to have a negative effect on L. crispatus
growth in our experimental system, it must be noted that
some douching products have been associated with B
streptococci and different Candida species (21). Douching
has also been associated with a non-regression of low-
grade squamous intraepithelial lesions (21). The use of
vaginal spermicides and vaginal medications has been
known to onset an unstable microflora and BV (22). It has
to also be noted that the effects of vaginal products on
bacterial growth can be selective and can vary among
commercial brands, as suggested by another in-vitro study,
which demonstrated differences among seven commercial
douches tested against Lactobacillus isolates as well as
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Fig. 1. Composite effect of vaginal products on L. crispatus
CFU. Bars represent logarithmically transformed means and
standard errors of the mean from triplicate CFU measurements
at (A) 2 h and (B) 24 h for each vaginal product exposed
to bacteria twice. P valuesB0.05 andB0.01 show significant
differences from the medium control. n.s.no significant
difference from control.
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BV associated bacteria (23). All three products tested were
estimated to be fairly acidic (Table 1), although the pH
varied within values typical for normal vaginal environ-
ment, except for the douche, which was more acidic.
Using the data that was amassed from this project,
more research can hopefully go into vaginal health and
development of probiotics for restoring and maintenance
of a healthy vaginal microflora. Conventional health care
wisdom has warned consumers against the use of douches
a due to their stripping the vagina of its protective lining
and altering its pH. Though the brand we tested did
not show to inhibit the growth in-vitro of L. crispatus,
frequent douching with this or other brands may throw
the vagina’s internal protective system off balance and
promote non-sexually and sexually transmitted infec-
tions. Regardless of this, millions of females still continue
to use it for personal and cultural reasoning. Hopefully
this research may blossom into a new field in the bio-
pharmaceutical market. Just as vaginal suppositories
exist containing estrogen replacement therapies and
anti-fungal agents to combat non-sexually transmitted
infections such as candida (yeast) and BV, we may
envision vaginal probiotic replacement therapies in the
future in order to promote vaginal health and curb
the frequency of reoccurring yeast infections and as a
supplement available to women who continue to use these
products. Preventative therapies are the path of modern
medicine. Finding treatments for tomorrows’ disease
may be the cloud with a silver lining for patients who
are afflicted, but preventing them is golden.
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